Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers. Ensituximab is the first development stage antibody therapeutic discovered by Precision Biologics and part of a pipeline of antibodies that target specific cancers.
